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Abstract: Introduction: Pituitary adenomas are commonly benign, slow-growing tumors that arise from cells in the pitu-
itary gland and consist of a common type of intracranial space-occupying lesions. Based on the functionality and
size of the adenoma, both medical and surgical approaches have been described. In this study, the authors aim
to determine the effects of contributing factors of patients with pituitary adenoma undergoing trans-sphenoidal
endoscopic surgery to their postoperative clinical status. Material and Methods: From March 2015 to November
2016, 100 patients diagnosed with pituitary adenoma confirmed by Magnetic Resonance Imaging (MRI) under-
went a trans-sphenoidal endoscopic approach in the department of Neurosurgery of Shohada Tajrish Hospital.
Demographic data, as well as pre-defined relevant contributing factors regarding clinical status, were recorded.
All patients underwent neuroimaging and neurological examination before surgery and were followed in the
postoperative period by repeated neurological examination, imaging surveys, and histopathological studies.
Statistical analysis was performed using SPSS program version 23. Results: This study consisted of 59 males
and 41 females with a mean age of 45.2 (24-63 years). Visual field defect (48%) was the most frequent finding,
while asymptomatic status (36%) was the second major clinical finding in the patients. Neuroimaging survey re-
vealed small tumor size and low extension type in 39 and 40 patients, respectively. Following the trans-sphenoid
surgical approach, intact adrenal, gonadal, and thyroid function was found in 92%, 92%, and 89% of the post-
operative phase cases. In the postoperative period, visual field defects, need for re-operation, diabetes insipidus
(DI), focal neurological deficits (FND), diplopia, post-operative hemorrhagic event, cerebrospinal fluid (CSF)
leak and meningitis were observed in 15%, 6%, 5%, 4%, 3%, 3%, 2% and 1% respectively. Moreover, three pa-
tients expired in the postoperative period. Our statistical analysis identified the presence of headache (P-value
0.039), functional pituitary adenoma(P-value 0.031), abnormal adrenal gland function(P-value 0.028), abnor-
mal thyroid function (P-value 0.003), and abnormal growth hormone (GH) levels (P-value 0.008) as the major
relevant contributing factors in determining the clinical status such as radiological imaging studies of the pi-
tuitary region, and hormonal profiles of these groups of patients. Conclusion: In general, the current study
revealed that headache, as well as the presence of functional pituitary adenoma and abnormal adrenal, thyroid,
and growth hormone levels, are among the major contributing factors in the determination of the postoperative
clinical status of patients diagnosed with pituitary adenomas underwent trans-sphenoid surgery.
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1. Introduction
A pituitary adenoma is a common intracranial tumor with
a 25% prevalence of people with a past or present diagno-
sis and an autopsy-found rate of 10 to 15% (1). The pituitary
adenoma is reported to 94 per 100,000 subjects of the Iranian
population (2). "The majority of pituitary adenoma cases
remains undiagnosed until late neurological and metabolic
symptoms which are related to the type of hormone with in-
creased secretion such as hyperprolactinemia, acromegaly,
Cushing’s disease and hyperthyroidism (3)." some symptoms
are related to the mass effect with parasellar and suprasel-
lar extensions such as headache and visual disturbances
(1, 3). Despite some pharmacological adventures and ad-
vanced radiotherapeutic treatments, surgical intervention
remains the most effective treatment strategy (3-5). Trans-
sphenoidal surgery is a safe choice in patients suffering from
acromegaly and Cushing’s disease without prolactinoma that
provides acceptable results than accompanying medical co-
morbidities (4, 5). The endoscopic approach provides eas-
ier access to the sella turcica with less adverse effects such as
nasal mucosal or septal injuries, sinusitis, intracranial nerve
injuries, diabetes insipidus, rhinorrhea of cerebrospinal fluid
(CSF), and meningitis (6-10). The authors aim to determine
the effects of contributing factors of patients diagnosed with
pituitary adenoma undergoing trans-sphenoidal endoscopic
surgery concerning their postoperative clinical status, the
primary clinical signs/symptoms at presentation, radiolog-
ical imaging of the pituitary region, size of tumors, visual
deficits, and hormonal profiles demonstrating relevant dis-
ordered secretion had to be available.
2. Material and Methods
A pituitary adenoma is a common intracranial tumor with
a 25% prevalence of people with a past or present diagno-
sis and an autopsy-found rate of 10 to 15% (1). The pituitary
adenoma is reported to 94 per 100,000 subjects of the Iranian
population (2). "The majority of pituitary adenoma cases
remains undiagnosed until late neurological and metabolic
symptoms which are related to the type of hormone with in-
creased secretion such as hyperprolactinemia, acromegaly,
Cushing’s disease and hyperthyroidism (3)." some symptoms
are related to the mass effect with parasellar and suprasel-
lar extensions such as headache and visual disturbances
(1, 3). Despite some pharmacological adventures and ad-
vanced radiotherapeutic treatments, surgical intervention
remains the most effective treatment strategy (3-5). Trans-
sphenoidal surgery is a safe choice in patients suffering from
acromegaly and Cushing’s disease without prolactinoma that
provides acceptable results than accompanying medical co-
morbidities (4, 5). The endoscopic approach provides eas-
ier access to the sella turcica with less adverse effects such as
nasal mucosal or septal injuries, sinusitis, intracranial nerve
injuries, diabetes insipidus, rhinorrhea of cerebrospinal fluid
(CSF), and meningitis (6-10). The authors aim to determine
the effects of contributing factors of patients diagnosed with
pituitary adenoma undergoing trans-sphenoidal endoscopic
surgery concerning their postoperative clinical status, the
primary clinical signs/symptoms at presentation, radiolog-
ical imaging of the pituitary region, size of tumors, visual
deficits, and hormonal profiles demonstrating relevant dis-
ordered secretion had to be available.
3. Results
In this study, males dominated the females’ population as
59 versus 41 cases (59% versus 41%). Men ranged from 27
to 63 years with a mean age of 46.6 years, while female age
ranged from 24 to 60 years with a mean age of 43.1 years.
While 45% of patients were older than 40 years, patients had
a mean age of 45.2 years. 36% of patients were asymptomatic
and consisted of the second most frequent manifestation
of pituitary adenoma following visual field defect with 48%
prevalence/ other less frequent clinical symptoms are men-
tioned in Table 1. Our neuroimaging survey resulted in de-
tecting small tumors and low extension type in 39 and 40 pa-
tients (40%), respectively. Preoperative hormonal assay re-
vealed functional pituitary adenoma in 31%, defective go-
nadal function in 28%, defective thyroid function in 26%, in-
tact thyroid function in 20%, non-functional pituitary ade-
noma in 12%, abnormal adrenal function in 11%, intact go-
nadal function in 8% and intact adrenal function in 6% of pa-
tients. Moreover, patients’ hormonal and neurological status
in the postoperative period is described in Table 2. Six cases
underwent reoperation, and 3 of them passed away in the
postoperative period. In addition, diabetes insipidus (DI),
diplopia, post-operative hemorrhagic event, cerebrospinal
fluid (CSF) leak and meningitis were observed in 5%, 3%,
3%, 2% and 1% respectively. Following trans-sphenoid en-
doscopic adenoma removal, postoperative MRI revealed no
residual tumor in 89 cases (89%). In comparison, others were
found to have a stable (non-progressive) residual tumor in 5
cases (5%), progressive tumor in 5 patients (5%), and recur-
rent one in 1 patient (1%) in the follow-up period. Statistical
analysis of these data with adverse postoperative outcomes
includes headache, functional pituitary adenoma, abnormal
function of adrenal, thyroid(hypopituitarism), growth hor-
mone(sensitivity decreases), and their correlation with asso-
ciated contributing factors and conditions revealed statisti-
cally significant in Table 3.
4. Discussion
In this study, the authors assessed the clinical outcomes
and adverse effects following trans-sphenoidal endoscopic
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adenoma resection to detect potential correlations between
these factors and adverse postoperative outcomes. The ma-
jority of pituitary adenomas are benign and manifest as hor-
monal over secretion or neurological and visual defects sec-
ondary to mass effects to the surrounding neuro-structures.
Cushing’s disease, hyperprolactinemia, and acromegaly are
among hypersecretory conditions, whereas the local mass
effect on the pituitary’s microscopic structures will cause
hypopituitarism. (11) Although medical therapy is benefi-
cial in prolactin-secreting pituitary adenomas (prolactino-
mas), trans-sphenoid surgical resection remains the stan-
dard gold treatment of these tumors. The addition of novel
technologies such as endoscopic probes enhanced surgical
accuracy and improved the extent of tumor resection. (12)
Greenfield et al. demonstrated that endoscopic surgery is a
minimally-invasive beneficial method in pituitary adenoma
cases, as was established in our study. (13) Also, de Divi-
tiis et al. assessed ten patients who underwent endoscopic
trans-sphenoidal surgical approach for pituitary adenoma
with complete and partial success in 70% and 20%, respec-
tively. (14) They reported a 20% rate for CSF rhinorrhea and
also showed a 10% mortality rate. However, in our study,
only three patients (three percent) died. Laufer et al. in the
United States assessed ten patients under endoscopic trans-
sphenoidal surgery for pituitary adenoma and found a 90%
success rate. (15) However, only one case with CSF rhinor-
rhea was seen, and diabetes insipidus was present in 60%,
persistent in five cases. Importantly, this complication was
seen in five cases in our study (5%), and only one case was
persistent. Cappabianca et al. assessed 33 patients under
endoscopic trans-sphenoidal surgery for pituitary adenoma,
and only three patients had side effects, including CSF leak,
bacterial meningitis, and seizure each one in one patient.
Our results were relatively similar. (16) Also, Dehdashti et al.
demonstrated that adverse effects and hospital stay are low in
patients under trans-sphenoidal surgery and our study. (17)
5. Conclusion
In general, it may be concluded that related factors for
the clinical status of patients with pituitary adenoma under
trans-sphenoidal endoscopic surgery are headache, Func-
tional pituitary adenoma, Abnormal adrenal function, Ab-
normal thyroid function, and Abnormal GH. However, fur-
ther studies with larger sample size and comparison with
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Table 1: The frequency of clinical manifestation in patients diagnosed with pituitary adenoma.
Clinical manifestation Yes (exhibited) No (not-exhibited)
Headache 18 82
Apoplexia 25 75
Visual defect 48 52
Rhinorrhea 25 75
Acromegaly 26 74
Congenital abnormality 29 71
Seizure 25 75
Body Mass Index (BMI) > 30 28 72
Hypopituitarism 16 84
No symptoms 36 64
Table 2: Postoperative patients’ status.
Postoperative evaluation Yes No
Normal adrenal function 92 8
Normal gonadal function 92 8
Normal thyroid function 89 11
Prolactin (normal range) 88 12
GH* (normal range) 86 14
Visual defect 15 85








Functional pituitary adenoma 0.031
Abnormal adrenal function 0.028
Abnormal thyroid function 0.003
Abnormal GH 0.008
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